Dr Reddy's launches generic prostate cancer treatment drug in US
The company has launched Abiraterone Acetate tablets USP in the strength of 250 mg, after the approval from the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE. The product is a generic version of Johnson & Johnson's Zytiga tablets, it added.
- Country:
- India
Pharma major Dr Reddy's Laboratories on Friday said it has launched generic Abiraterone Acetate tablets, used for treatment of prostate cancer, in the US market. The company has launched Abiraterone Acetate tablets USP in the strength of 250 mg, after the approval from the United States Food and Drug Administration (USFDA), Dr Reddy's Laboratories said in a filing to the BSE.
The product is a generic version of Johnson & Johnson's Zytiga tablets, it added. According to data from IQVIA Health, Zytiga brand and generic market had US sales of around USD 454 million MAT for the 12 months ended March 2020, Dr Reddy's Laboratories said.
Shares of Dr Reddy's Laboratories on Friday closed at Rs 4,010 per scrip on the BSE, up 0.13 per cent from its previous close..
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Woman strangled to death in Mumbai, house-help's involvement suspected
Kerala: Poll officials suspended after three voter ID cards issued to single voter in Beypore
Govt agrees to suspend requirement for councils to comply with Significant Natural Areas
Telangana: Suspended intelligence officer accused of destroying official data arrested
Police say suspect in a Hawaii acid attack on a woman plotted with an inmate to carry out 2nd attack